Geode Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-244,151
| Closed | -$650K | – | 4705 |
|
|
2024
Q1 | $650K | Buy |
244,151
+13,398
| +6% | +$33.2K | ﹤0.01% | 3520 |
|
|
2023
Q4 | $547K | Buy |
230,753
+9,239
| +4% | +$16.4K | ﹤0.01% | 3576 |
|
|
2023
Q3 | $310K | Buy |
221,514
+37,071
| +20% | +$89K | ﹤0.01% | 3801 |
|
|
2023
Q2 | $559K | Sell |
184,443
-260,946
| -59% | -$1.01M | ﹤0.01% | 3600 |
|
|
2023
Q1 | $2.78M | Buy |
445,389
+13,775
| +3% | +$83.9K | ﹤0.01% | 2895 |
|
|
2022
Q4 | $2.63M | Buy |
431,614
+10,905
| +3% | +$88.8K | ﹤0.01% | 2939 |
|
|
2022
Q3 | $5.03M | Buy |
420,709
+10,225
| +2% | +$134K | ﹤0.01% | 2674 |
|
|
2022
Q2 | $5.18M | Buy |
410,484
+45,381
| +12% | +$422K | ﹤0.01% | 2682 |
|
|
2022
Q1 | $4.11M | Buy |
365,103
+1,471
| +0.4% | +$16.2K | ﹤0.01% | 2911 |
|
|
2021
Q4 | $6.44M | Buy |
363,632
+26,410
| +8% | +$557K | ﹤0.01% | 2743 |
|
|
2021
Q3 | $7.76M | Buy |
337,222
+99,973
| +42% | +$2.18M | ﹤0.01% | 2649 |
|
|
2021
Q2 | $5.52M | Sell |
237,249
-1,332
| -0.6% | -$33.9K | ﹤0.01% | 2829 |
|
|
2021
Q1 | $7.43M | Buy |
238,581
+209,101
| +709% | +$7.29M | ﹤0.01% | 2563 |
|
|
2020
Q4 | $1.17M | Buy |
+29,480
| New | +$1.18M | ﹤0.01% | 3320 |
|
Geode Capital Management's KNTE Position: Q2 2024 in Review
Geode Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 244,151 shares — an estimated $650K sold.
Geode Capital Management first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $7.76M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Geode Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 244,151 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $650K.
- Geode Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Geode Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $7.76M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.